Eli Lilly & (LLY) Stock
Major pharmaceutical group with diabetes and obesity medicines. Here's the price, business snapshot, and what's worth knowing about Eli Lilly & in June 2026.
Eli Lilly and Company (LLY) is a major US pharmaceutical group with a broad portfolio spanning diabetes, oncology, immunology and neuroscience. With a market capitalisation around $756.8bn, Lilly is known for strong commercial medicines such as GLP-1 and dual-agonist therapies that have driven recent sales growth, alongside a diversified R&D pipeline. Investors should know Lilly combines steady cash-generating marketed products with growth from newer launches and late‑stage candidates, but faces typical sector risks: regulatory review, patent expiries, pricing scrutiny and competition. Financials can be resilient but are sensitive to trial outcomes and reimbursement decisions. As general information, this summary is educational not personal financial advice — returns are not guaranteed and values can fall as well as rise. Prospective investors should consider their objectives, time horizon and risk tolerance, and may wish to consult an authorised financial adviser before investing.
Why It’s Moving
Eli Lilly’s consensus stays constructive as analysts lean on blockbuster drug momentum and long-run growth expectations.
- Analyst sentiment remains favorable, with most coverage still rating the stock Buy or Strong Buy, signaling confidence in Lilly’s earnings power and pipeline.
- The market is still focused on Lilly’s weight-loss and diabetes drugs, which continue to shape expectations for revenue durability and margin expansion.
- With no major earnings or new product catalyst in the last seven days, trading has been more about valuation checks and broader healthcare-sector positioning than a single headline-driven move.
Eli Lilly’s consensus stays constructive as analysts lean on blockbuster drug momentum and long-run growth expectations.
- Analyst sentiment remains favorable, with most coverage still rating the stock Buy or Strong Buy, signaling confidence in Lilly’s earnings power and pipeline.
- The market is still focused on Lilly’s weight-loss and diabetes drugs, which continue to shape expectations for revenue durability and margin expansion.
- With no major earnings or new product catalyst in the last seven days, trading has been more about valuation checks and broader healthcare-sector positioning than a single headline-driven move.
When is the next earnings date for Eli Lilly & Co (LLY)?
LLY’s next earnings date is expected to be August 5, 2026, before the market opens. The report should cover Q2 2026. This timing is consistent with Eli Lilly’s typical early-August earnings pattern.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Eli Lilly's stock with a target price of $903.09, indicating growth potential.
Financial Health
Eli Lilly is performing well with strong revenue and cash flow, indicating healthy business operations.
Dividend
Eli Lilly's low dividend yield of 0.55% indicates limited income for investors seeking dividends. If you invested $1000 you would be paid $6.23 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring LLY
The GLP-1 Insurance Gap Reshaping Weight Care in 2026
Cigna's decision to drop coverage for popular GLP-1 weight-loss drugs like Wegovy and Zepbound for its employees signals a potential shift in employer-sponsored healthcare. This policy change could drive significant demand toward affordable direct-to-consumer telehealth platforms and alternative digital weight management programs.
Published: 3 June 2026
Explore BasketAI-Driven Pharma Stocks | Pipeline Innovation
Novo Nordisk's partnership with OpenAI highlights a massive shift as major drugmakers integrate generative AI into their core operations. This basket captures the pharmaceutical giants optimizing their pipelines alongside the tech titans providing the underlying AI infrastructure.
Published: 15 April 2026
Explore BasketUS Pharma Reshoring | CDMOs & Supply Chain Stocks
The Trump administration is implementing sweeping 100% tariffs on imported brand-name drugs to force pharmaceutical companies into producing their medicines stateside. This aggressive policy shift creates a highly lucrative environment for US-based contract manufacturers and domestic healthcare supply chain operators as global drugmakers rush to reshore their operations.
Published: 4 April 2026
Explore BasketCould Dermatology Biologics Unlock Predictable Revenue?
Eli Lilly's eczema drug EBGLYSS has demonstrated sustained, multi-year effectiveness, highlighting the lucrative potential of targeted biologic therapies. This clinical milestone validates the broader dermatology market, creating opportunities for biopharmaceutical companies developing innovative skin treatments.
Published: 28 March 2026
Explore BasketInvestment Opportunities in RNA Therapeutics Explained
Eli Lilly's $2.4 billion acquisition of Orna Therapeutics signals a major bet on circular RNA and in vivo cell engineering. This theme focuses on the broader ecosystem of companies developing the next-generation platforms and delivery technologies essential for advancing genetic medicine.
Published: 10 February 2026
Explore BasketPharma Buyouts Explained | Healthcare M&A Analysis
Merck's decision to end its acquisition talks with Revolution Medicines highlights the high-stakes environment for biotech M&A. This failed deal could signal an opportunity for other pharmaceutical giants to acquire promising oncology assets, creating a ripple effect across the sector.
Published: 26 January 2026
Explore BasketAI Drug Discovery | Biotech Investment Opportunities
NVIDIA and Eli Lilly have launched a $1 billion AI lab to revolutionize the drug discovery process. This partnership highlights a burgeoning investment opportunity in companies at the intersection of artificial intelligence and biotechnology.
Published: 13 January 2026
Explore BasketU.S. Drug Manufacturing | Multi-Billion Investment Push
Johnson & Johnson is the latest major drugmaker to lower U.S. prices in exchange for tariff exemptions, joining a broad industry trend. This government-led initiative is sparking a multi-billion dollar investment wave into domestic manufacturing, creating a significant opportunity for companies supporting the U.S. pharmaceutical supply chain.
Published: 10 January 2026
Explore BasketDrug Pricing Deals Drive US Manufacturing in 2025
Johnson & Johnson secured a deal with the U.S. government to lower drug prices in exchange for tariff exemptions, expanding on a major policy trend. This theme identifies opportunities among pharmaceutical companies and domestic manufacturers benefiting from government incentives to onshore production.
Published: 9 January 2026
Explore BasketRadiopharma Revolution: Promise Meets Market Risk
Aktis Oncology's highly successful and upsized IPO, strongly backed by pharma giant Eli Lilly, signals a surge of investor confidence in radiopharmaceutical cancer therapies. This theme focuses on the companies poised to ride this wave of investment and innovation in one of biotech's most promising frontiers.
Published: 9 January 2026
Explore BasketTYK2 Inhibitors: Might Oral Drugs Rule Autoimmune?
Alumis's breakthrough trial results for its oral psoriasis drug have highlighted the massive potential of advanced autoimmune therapies. This theme focuses on the pharmaceutical companies pioneering next-generation oral treatments, particularly selective TYK2 inhibitors, which represent a new frontier in convenient and effective patient care.
Published: 7 January 2026
Explore BasketOral Obesity Treatments: Investment Theme Explained
Novo Nordisk has launched the first oral GLP-1 weight loss medication, Wegovy, representing a major evolution in the obesity treatment landscape. This shift from injections to pills creates an investment opportunity in pharmaceutical innovators and the digital health companies enabling broad access.
Published: 6 January 2026
Explore BasketDrug Pricing Power | Major Pharma Stocks 2025
Following plans by major drugmakers to raise prices on hundreds of medications, the pharmaceutical industry is showcasing its significant pricing power. This development highlights an investment opportunity centered on established pharmaceutical companies capable of translating market dominance into revenue growth.
Published: 2 January 2026
Explore BasketM&A Activity Overview | Pharma Biotech Investments
Merck's $9.2 billion acquisition of Cidara Therapeutics aims to bolster its antiviral portfolio ahead of the Keytruda patent expiration. This strategic purchase signals a broader investment opportunity in biotech firms with advanced clinical assets, positioning them as attractive targets for major pharmaceutical companies.
Published: 15 November 2025
Explore BasketObesity Drug Pricing | Pharma Investment Theme
New agreements with Eli Lilly and Novo Nordisk are set to dramatically lower the cost of popular weight-loss drugs, making them accessible to millions through Medicare. This creates an investment opportunity centered on the major pharmaceutical companies involved and the broader supply chain that will support the expected surge in demand.
Published: 8 November 2025
Explore BasketObesity Drug Stocks: Medicare Coverage Trade-offs
A new agreement between the Trump administration, Eli Lilly, and Novo Nordisk will dramatically lower the cost of GLP-1 weight loss drugs and expand Medicare coverage. This move is expected to significantly increase patient access and boost sales, creating opportunities for the drug manufacturers and their key suppliers.
Published: 7 November 2025
Explore BasketPharma Onshoring: What's Next for US Drug Supply
Merck is investing $3 billion in a new Virginia plant, signaling a major push for domestic pharmaceutical production. This theme focuses on companies poised to benefit from the broader trend of onshoring the U.S. drug supply chain.
Published: 21 October 2025
Explore BasketEarly Alzheimer's Detection: Could Blood Tests Replace Scans?
The FDA's approval of Roche and Eli Lilly's blood test marks a pivotal shift toward early and accessible Alzheimer's diagnosis in primary care. This breakthrough is expected to accelerate growth for companies in the diagnostics sector and expand the market for new Alzheimer's treatments.
Published: 14 October 2025
Explore BasketPharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: 12 October 2025
Explore BasketDomestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: 26 September 2025
Explore BasketNovo Nordisk Stock Risks: Healthcare Diversification
As Africa's healthcare needs grow, demand for innovative treatments for chronic conditions like diabetes is on the rise. This basket offers potential exposure to this trend through leading global pharmaceutical and healthcare companies listed on US and EU exchanges.
Published: 23 September 2025
Explore BasketPharma Investment Basket Explained (Eli Lilly+)
Nigeria's growing population is increasingly seeking exposure to global health advancements, particularly from leading pharmaceutical innovators. This basket provides potential exposure to this trend through a collection of US and EU-listed pharmaceutical, biotechnology, and healthcare supply chain companies.
Published: 11 September 2025
Explore BasketObesity Treatment (Pharma Giants vs Biotech Firms)
Novo Nordisk's major restructuring, driven by intense competition from Eli Lilly, highlights the high-stakes battle in the weight-loss drug market. This theme focuses on other pharmaceutical companies that could benefit from this rivalry, either as innovators with next-generation treatments or as potential acquisition targets.
Published: 10 September 2025
Explore BasketCardio-Metabolic Drugs: Beyond Weight Loss Benefits
Following new data showing Novo Nordisk's Wegovy has superior cardiovascular benefits over a key rival, the competitive landscape for weight-loss drugs has intensified. This theme focuses on the pharmaceutical giants battling for dominance and the innovative biotechs whose research in related metabolic and cardiovascular fields is now more valuable than ever.
Published: 1 September 2025
Explore BasketBeyond The Needle: The Oral GLP-1 Revolution
Eli Lilly's successful trial of its oral weight-loss drug, orforglipron, signals a major shift in the treatment landscape for obesity and diabetes. This theme focuses on the innovative pharmaceutical companies developing the next wave of convenient, non-injectable therapies poised to challenge the dominance of current market leaders.
Published: 28 August 2025
Explore BasketOral Obesity Treatments: Beyond The Needle
Following successful Phase 3 trials for its oral weight-loss drug, orforglipron, Eli Lilly is positioned to enter the lucrative obesity treatment market. This development creates a new investment theme focused on pharmaceutical companies developing patient-friendly, oral alternatives to injectable GLP-1 therapies.
Published: 27 August 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: 19 August 2025
Explore BasketPioneering Sickle Cell Solutions
Pfizer's recent failure in a key sickle cell disease trial highlights the urgent need for new therapies. This setback creates a significant opportunity for innovative biotech companies developing alternative treatments, including potentially curative gene therapies.
Published: 17 August 2025
Explore BasketThe Global Weight-Loss Drug Price Shift
Eli Lilly's significant price hike for Mounjaro in the UK, driven by U.S. political pressure, highlights a new global pricing strategy for blockbuster drugs. This creates a potential opportunity for competitors in the booming weight-loss market as patients and providers may seek more affordable alternatives.
Published: 15 August 2025
Explore BasketExecutive Conviction In The GLP-1 Market
Following a stock drop from a clinical trial setback, Eli Lilly executives made significant share purchases, signaling strong belief in the company's future. This insider confidence highlights a potential investment opportunity in the rapidly growing and competitive GLP-1 weight-loss drug market.
Published: 13 August 2025
Explore BasketNext-Generation Antibiotic Innovators
With the FDA granting priority review to GSK's new oral antibiotic for gonorrhea, a new front has opened in the fight against drug-resistant bacteria. This theme focuses on the biotechnology companies developing the next generation of antibiotics to address this critical and growing public health need.
Published: 12 August 2025
Explore BasketPharma's Pricing Pressure
In response to a presidential ultimatum for 17 drug makers to slash U.S. prices, the pharmaceutical industry faces a major regulatory challenge. This event creates a potential investment opportunity in companies positioned to gain from the pricing disruption, including generic manufacturers.
Published: 3 August 2025
Explore BasketThe Alzheimer's Treatment Ecosystem
Following the EU regulator's approval of Eli Lilly's Alzheimer's drug, Kisunla, a new investment opportunity has emerged. This theme focuses on companies that provide essential support services, such as genetic testing and advanced imaging, which are crucial for the drug's administration and monitoring.
Published: 27 July 2025
Explore BasketPowering The AI Supercluster
OpenAI and Oracle are partnering on a $500 billion project to build a massive AI supercluster in the U.S. This historic infrastructure investment creates a significant opportunity for companies that supply the essential power, cooling, and construction services needed to support this build-out.
Published: 23 July 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: 15 July 2025
Explore BasketSafer Alzheimer's Treatments
This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Published: 11 July 2025
Explore BasketEarnings Over Headwinds
A carefully selected collection of companies showing exceptional earnings growth despite market challenges. These stocks were handpicked by our analysts for their ability to maintain strong performance even when facing trade tensions and economic uncertainty.
Published: 2 July 2025
Explore BasketGlobal Giants
Own a piece of the world's most powerful companies in one portfolio. These industry titans have been carefully selected by our analysts for their market dominance, stability, and long-term growth potential.
Published: 18 June 2025
Explore BasketSynthetic-Bio Foundries
Discover companies that are programming living cells to create the materials of tomorrow. These carefully selected stocks represent pioneers in replacing petrochemical processes with cleaner, more efficient biological alternatives - essentially turning microbes into tiny manufacturing plants.
Published: 17 June 2025
Explore BasketBoomer Stocks
Discover a collection of iconic, industry-leading companies with deep market roots and reliable dividend histories. These household names have been carefully selected by our analysts for their strong brands, steady cash flow, and potential for long-term stability.
Published: 17 June 2025
Explore BasketFuture Tech: World Changing Ideas
Get ahead of tomorrow's innovations with this collection of stocks pushing technological boundaries. Our analysts have carefully selected companies developing flying cars, breakthrough medical treatments, and robotic surgery that could reshape our future.
Published: 25 May 2025
Explore BasketModerate Volatility Stocks
These carefully selected stocks offer the perfect balance between growth potential and stability. Our professional analysts have handpicked companies that can help you participate in market gains while potentially reducing downside risk during turbulent times.
Published: 23 May 2025
Explore BasketCopy a $11.55Trn Asset Manager
Want to invest like the pros? This collection features stocks that BlackRock, the world's largest asset manager, has in their portfolio. These carefully selected investments represent the strategy of financial experts who manage trillions in assets.
Published: 21 May 2025
Explore BasketLargest U.S Stocks
Everything is bigger in America! This collection features some of the world's largest companies, carefully selected by our professional analysts. From tech giants to energy behemoths, these stocks represent the backbone of the American economy.
Published: 17 May 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: 6 May 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline-led growth
Late-stage candidates and recent product roll-outs can boost revenue, though outcomes and timelines are uncertain and can affect share performance.
Global commercial reach
A wide geographic footprint helps diversify sales, but reimbursement policies and pricing pressure vary by market and may impact returns.
R&D and innovation
Heavy R&D investment fuels long-term potential, while the opposite side of the coin is the cost and risk of trials and regulatory review.
Compare Eli Lilly with other stocks
Eli Lilly vs Novo Nordisk
Eli Lilly vs Novo Nordisk: A Stock Comparison
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
